|A New Way to Identify Patients likely to have Multiple Sclerosis
Diagnosing Multiple Sclerosis (MS) can be very difficult and time consuming, sometimes taking months to years to receive a diagnosis.
Initially, physicians need to exclude other diseases that have similar symptoms. In addition, MRI examinations are not always clear and clinical symptoms are often inconclusive. These factors make diagnosing MS a complex and sometimes lengthy process, which can be very frustrating for individuals and physicians.
In order to help patients and physicians identify patients with a high probability of having MS, Glycominds has introduced the gMS®Dx test, a new blood test for MS biomarkers. This revolutionary test helps physicians identify the patients who have had a first neurological event and a positive MRI that are likely to develop MS.
Why use the gMS®Dx test?
•NEW - First blood based biomarker test validated for MS
•POWERFUL - High positive predictive value for identifying patients likely to have MS after the first neurological event
•The gMS®Dx test differentiates MS from other neurological diseases
•SIMPLE - Easy, non-invasive test, that complements MRI
The gMS®Dx Test is performed exclusively by Glycominds Laboratory Services at our CLIA approved lab in Simi Valley, California (CA License Number: CLF00340032).
Patent- US 7,537,900